Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trial
Question
Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trial
Direct answer
Regulatory trial clearance from BfArM opens German patient enrollment, progressing clinical validation required for European CE Mark commercial access for the DurAVR valve. — bullish pressure on AVR via clinical pathway milestone progress toward European commercialization.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-20
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trial”, revision 1, evidence through 2026-10-20. https://marketontology.com/catalysts/2026-10-20/anteris-wins-german-bfarm-clearance-for-duravr-paradigm-heart-valve-trial-31081a
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| AVR | ▲Bull | 1–4 weeks | clinical pathway milestone progress toward European commercialization | 74 |
Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trial
Regulatory trial clearance from BfArM opens German patient enrollment, progressing clinical validation required for European CE Mark commercial access for the DurAVR valve. — bullish pressure on AVR via clinical pathway milestone progress toward European commercialization.
BfArM clearance allows Anteris to initiate PARADIGM patient recruitment in Germany.
- SourceBfArM clearance allows Anteris to initiate PARADIGM patient recruitment in Germany.
- TransmissionRegulatory trial clearance from BfArM opens German patient enrollment, progressing clinical validation required for European CE Mark commercial access for the DurAVR valve.
- SummaryAnteris Technologies received regulatory approval from Germany's BfArM for the PARADIGM clinical trial. The study investigates the DurAVR Transcatheter Heart Valve for severe aortic stenosis treatment. Clearance establishes German clinical site recruitment for pivotal transcatheter heart valve data.
- AVRDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AVR closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AVR price vs. pre-event level
- AVR volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.